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Abstract 
Mastoparan is a typical cationic and amphipathic tetradecapeptide found in wasp venom and exhibits 
potent biological activities. Yet, compared with other insect-derived peptides, such as melittin from 
the bee venom, this family have been underrated. Herein, we evaluated the biological activities of 
mastoparan-C (MP-C), which was identified from the venom of the European Hornet (Vespa crabro), 
and rationally designed two analogues (a skeleton-based cyclization by two cysteine residues and an 
N-terminal extension via tat-linked) for enhancing the stability of the biological activity and 
membrane permeability, respectively. Three peptides possessed broadly efficacious inhibiting 
capacities towards common pathogens, resistant strains, as well as microbial biofilm. Although, 
cyclized MP-C showed longer half-life time than the parent peptide, the lower potency of 
antimicrobial activity and higher degree of haemolysis were observed. The tat-linked MP-C 
exhibited more potent anticancer activity than the parent peptide, but it also loses the specificity. 
The study revealed that MP-C is good candidate for developing antimicrobial agents and the 
targeted-design could improve the stability and transmembrane delivery, but more investigation 
would be needed to adjust the side effects brought from the design. 
Key words: mastoparan-C, peptide design, antimicrobial, anticancer  
Introduction 
Wasp venom contains numerous bioactive 
substances that are of importance to the animal for 
hunting and defending against intruders, but have 
also attracted attention because of their potential 
physiological, pharmacological, and therapeutic 
applications 1-4. Of the many small venom-derived 
peptides that are known, mastoparan and 
mastoparan-like peptides are the best characterised 
candidates 4, 5. Although there is much sequence 
heterogeneity among mastoparans, the family 
nevertheless displays several common structural 
characteristics among its members. For example, the 
majority of mastoparans are 14 amino acids in length, 
most of which are the hydrophobic residues leucine, 
isoleucine, valine, and alanine 4, 6, 7. In addition, the 
peptides tend to be polycationic because of the 
numerous lysine residues and also possess an 
amidated C-terminus 8. Finally, whereas mastoparans 
typically possess a random-coil structure in an 
aqueous solution, they partially convert to an 
α-helical conformation in an amphiphilic 
environment 9. 
Pharmacologically, mastoparans also represent a 
promising group of small peptides, with those 
mastoparans that have been characterised variously 









anisms, inhibitory effects against tumour 
proliferation, and stimulating serotonin release from 
platelets and mast cell degranulation 10-12. Effective 
active concentrations are also often low, particularly 
for antimicrobial activity where suitable inhibitory 
concentrations are on the order of micromolars or 
even lower 13-15. Importantly, recent studies have also 
shown that mastoparans are effective against some 
clinically resistant microbial strains. For instance, Lin 
and colleagues demonstrated that multidrug-resistant 
Acinetobacter baumanni, one of major contributors to 
nosocomial infections, is compromised by 
mastoparan-AF in low dosages 15. 
However, the promise shown by mastoparans as 
potential drug candidates is offset currently by their 
haemolytic activity and other reported toxic effects 6, 
16. In addition, like with other natural antimicrobial 
peptides, additional non-negligible issues, including 
restricted half-lives and stability in addition to 
potential, general toxicity must be addressed prior to 
therapeutic application in clinical settings 17, 18. A 
useful strategy in this regard is targeted engineering, 
which proximately aims to optimize therapeutic 
activity, in part by reducing toxicity toward normal 
cells, and ultimately enables us to further explore the 
structure-function interrelationship of small peptides 
with the goal of improving targeted design changes. 
Commonly implemented changes in this context 
include amino-acid replacement to reduce toxicity 
(e.g., by replacing highly hydrophobic amino acids 
with isoleucine) or to alter the α-helical content to 
enhance cell-selectivity or anti-biofilm property 19, 20as 
well as altering the length of the primary structure. 
For instance, KS-30, a truncated sequence that was 
derived from human cathelicidin LL-37 by removing 
seven residues at the N-terminus of the latter, was 
shown to exert more potent antimicrobial activity 21. 
Alternatively, short foreign peptide sequences can 
also be added to antimicrobial peptides as part of a 
directed therapeutic drug design, particularly 
CPP/PTD application (frequently artificial sequence 
(polyarginine and polylysine)) to improve drug 
delivery, but also the virus fragments VP22 and Tat or 
the insect peptide penetratin 22, 23. Finally, 
skeleton-based end-capping of either the N- or 
C-terminus (e.g., via cyclization) has also been 
exploited to limit conformational flexibility and to 
avert enzymatic degradation.  
In this paper, we broadly investigate the 
antimicrobial peptide mastoparan-C (MP-C) from the 
European Hornet (Vespa crabro) venom with respect to 
its therapeutic potential against common pathogens, 
antibiotic-resistant strains, and microbial biofilms. In 
addition to our examinations of the natural peptide, 
we also derived and tested two analogues of it that 
were designed for either improved stability in serum 
(by introducing a disulphate bridge between N- and 
C- terminus) or enhanced intracellular delivery to 
possibly improve anticancer activity (by introducing a 
TAT sequence). For both analogues, we assessed the 
degree to which the specific goals of the designed 
changes were met and compared their biological 
activities to the natural, parent peptide. Altogether, 
this study yields important information regarding the 
potential of MP-C as a drug candidate as well as how 
it is affected by possible design changes to increase its 
therapeutic potential. 
Experimental approach 
Design and synthesis of MP-C and the two 
analogues 
We obtained the primary sequence for MP-C 
(LNLKALLAVAKKIL-NH2) from the literature 24, 25. 
From this natural, parent sequence, we derived two 
artificial analogues designed either to enhance its 
stability or its cell-based targeting activity. In the 
former case, given that a cyclic structure makes 
polypeptides more resistant to degradation, we 
introduced one cysteine at each of the N- and 
C-termini causing MP-C to form a loop structure 
(cMP-C; CLNLKALLAVAKKILC-NH2). In the latter 
case, we added a short cell-penetrating peptide 
(RKKRRQRRR) to the N-terminal of the parent 
sequence (tMP-C; RKKRRQRRRLNLKALLAVAKKIL 
-NH2). This sequence is derived from the basic 
domain (residues 48-57) of the HIV-1 TAT protein and 
is indicated to be the smallest fragment of the protein 
that maintains the ability to be assimilated by 
eukaryotic cell membranes 26-29 without any biological 
response 30, 31.  
Sufficient quantities to evaluate the bioactivities 
of all three peptides were obtained using the 
automatic PS4 peptide synthesizer (Protein 
Technologies, USA) along with Rink amide resin and 
standard Fmoc-chemistry. Cleavage of the primary 
products from the resin and subsequent deprotection 
used a mixture of trifluoroacetic acid (TFA), 
ethanedithiol (EDT), triisopropylsilane (TIPS) and 
water (94:2:2:2 (v/v)). Prior to lyophilisation, cMP-C 
was dissolved in 0.2% of hydrogen peroxide in 
0.05/19.95/80.00 (v/v/v) TFA/ water/ acetonitrile 
for 0.5h to get the loop structure via sulfhydryl 
oxidization. Finally, each synthetic peptide was 
purified using RP-HPLC (Phenomenex C-5 column, 
0.46 cm × 25 cm) and its purity was confirmed using 
MALDI-TOF mass spectrometry (supplementary in 
Figure S1) (Perseptive Biosystems, MA, USA).  





Circular Dichroism (CD) analysis of synthetic 
peptides 
The secondary structure of each peptide was 
estimated using a CD spectrometer (Jasco J851, USA). 
Specifically, the parameters were One hundred µM of 
each peptide, which was dissolved in 10 mM 
ammonium acetate (NH4AC) buffer or 50 % 
trifluoroehanol (TFE) (v/v in 10 mM NH4AC) 
respectively, was loaded in a cuvette (1-mm path 
length). For the analysis, three passes (“accumu-
lation”) within the range of 190-260 nm were made at 
20 °C at a scanning speed of 200 nm/min, a 
bandwidth of 1 nm, and a data pitch of 0.5 nm. The 
percentage of the α-helix structure was predicted via 
K2D method in DichroWeb website (http:// 
dichroweb.cryst.bbk.ac.uk/html/home.shtml). 
Stability in serum/reaction kinetics 
Fifty μM of each peptide was incubated in 
RPMI-1640 culture medium (Invitrogen, Paisley, UK) 
supplemented with 10% (v/v) of fetal bovine serum 
(FBS) (Sigma-Aldrich, St. Louis, MO, USA) at 37 ºC for 
24 h. At four-hour time intervals, 300 μL of the 
reaction solution was added to 600 μL of 96% ethanol 
to precipitate the serum proteins. The cloudy reaction 
sample was then cooled at 4 ºC for 15 min before 
being spun at 18,000× g for 2 min to remove the 
precipitated serum proteins in the pellet. 
Subsequently, each reaction supernatant was 
analysed using RP-HPLC and MALDI-TOF to provide 
both quantitative and qualitative results of the 
degradation process. The percentage of each peptide 
that remained was calculated by comparing the 
corresponding peak area at a given time point with 
that of the original stock solution without serum. 
Antimicrobial assays 
The minimal inhibitory concentrations (MICs) of 
all three synthesized peptides were determined 
against S. aureus (NCTC 10788), E. coli (NCTC 10418) 
and C. abicans (NCTC 1467) as well as against the 
resistant microorganisms methicillin-resistant S. 
aureus (MRSA; ATCC 12493), P. aeruginosa (ATCC 
27853) and E. faecalis (NCTC 12697), each of which had 
been cultured in Mueller-Hinton Broth (MHB). 
Cultures of each microorganism (105 colony forming 
units (CFU)/mL) were inoculated with peptide 
solutions in a concentration range of 1 to 512 μM (in 
two-fold dilutions) in a 96-well plate (100 μL per well) 
and incubated at 37 °C in a humidified atmosphere for 
16-24 h. Thereafter, the absorbance values of each well 
was determined at 550 nm using a Synergy HT plate 
reader (Biotech, USA) and the MIC was defined as the 
lowest concentration of the respective peptide that 
resulted in no apparent growth of the microorganism. 
In addition, 20 uL of a mixture from each well was 
inoculated on Mueller Hinton agar (MHA) plates. The 
corresponding peptide concentration where no 
bacterial communities grew was defined as the 
minimum bactericidal concentration (MBC). 
Anti-biofilm assay  
For measuring the minimum biofilm inhibitory 
concentration (MBIC), we used the two common 
biofilm-forming bacteria P. aeruginosa and S. aureus, 
which were cultured in Luria Broth (LB) and Tryptic 
Soy Broth (TSB), respectively 32-34. Peptide solutions 
from 1 - 512 μM (again in two-fold dilution) were 
incubated with 106 CFU/mL of each bacterial culture 
in the corresponding medium and again placed in the 
wells of 96-well plate (100 μL per well). After 18 h of 
incubation (at 37 °C and 200 rpm), each well was 
rinsed twice with deionized water and stained with 
125 μL of 0.1% Crystal Violet. Excess stain was 
removed by further rinsing with deionized water. 
After air drying overnight, 150 μL of 30% glacial acetic 
acid was added to each well and the absorbance at 595 
nm was measured using the Synergy HT plate reader. 
The assays to determine the minimum biofilm 
eradication concentration (MBEC) followed a similar 
procedure except that 100 μL of each bacterial culture 
was first seeded in a 96-well plate and incubated for 
18 h (at 37 °C and 200 rpm) to form the biofilm. After 
the planktonic phase was removed, peptide solutions 
in the standard concentrations were added to the 
biofilms that had formed in each well. After 24 h 
incubation, the biofilms were stained and measured 
as described above for MBIC. 
Both MBIC and MBEC were defined in an 
analogous fashion to MIC and MBC, respectively. 
Membrane permeability assay 
Membrane permeability was evaluated using a 
SYTOX Green Nucleic Acid Stain (Life Technologies, 
UK) assay. Cells from a culture of S. aureus that was in 
the logarithmic growth phase were centrifuged, 
washed and re-suspended in 5% TSB in 0.85% NaCl 
solution. Thereafter, 50 µL of the bacterial suspension 
(1 x 107 CFU/mL) was incubated for 2 h at 37 ˚C with 
40 µL of peptide solution in final concentrations of 1-, 
2- and 4-fold of the respective MICs in a black 96 well 
plate (Sterilin, UK) that was shielded from any light. 
Equivalent bacteria cells treated with 70% isopropanol 
or 5% TSB only served as positive and negative 
controls, respectively. After two hours, SYTOX green 
nucleic acid stain was added to each well at the final 
concentration of 5 µM and allowed to incubate for 5 
min after which the fluorescent intensity (excitation at 
485 nm and emission at 528 nm) was recorded using 
an ELISA plate reader (Biolise BioTek EL808). 





On the other hand, to obtain the fluorescence 
kinetics of membrane permeabilisation, 50 µL of 
bacterial suspension was added to 40 µL of peptide 
solution in final concentrations of 4-fold of the 
respective MICs in a black 96 well plate. And the 5 µM 
SYTOX green nucleic acid stain was mixed with the 
reaction immediately. Thereafter, changes in memb-
rane permeability were quantified via time-course 
analyses over a period of 40 min with data collection 
occurring at one-minute intervals and the examin-
ation method of fluorescent intensity see above.  
MTT anti-cancer assay 
Each of the five cancer cell lines — non-small cell 
lung cancer H157, melanocyte MDA-MB-435S, human 
prostate carcinoma PC-3, human glioblastoma 
astrocytoma U251MG, human breast cancer MCF-7 — 
as well as the cell line for normal human microvessel 
endothelial cells HMEC-1 were seeded into a 96-well 
plate at densities of 5000 cells/well. After incubation 
for 24 h at 37 ºC with 5% CO2, the cells were starved 
for 6 h by replacing the medium with serum-free 
medium. Thereafter, synthesized peptides (in ten-fold 
concentrations from 10-4 to 10-9 M in serum-free 
medium) were incubated with the cells for 24 h after 
which 10 μL of MTT solution (5mg/ml) was added to 
each well under dark conditions. Following a further 
4-6 h of incubation, 100 μl of DMSO superseded 
medium was added to each well to dissolve the 
formazan crystals. The OD value of each well was 
read by the Synergy HT plate reader at 550 nm. 
Haemolysis assay 
Finally, to determine the toxicity of the peptides 
to normal mammalian cells, a 2% solution of horse 
erythrocytes was re-suspended in PBS solution and 
incubated with each peptide at the standard 
concentrations (i.e., from 1 to 512 μM) for 2 h at 37 ºC. 
Equivalent cells treated with PBS or 1% Triton X-100 
served as the positive and negative controls, 
respectively. Following centrifugation at 900× g for 5 
min, 100 μL of the supernatant from each tube was 
transferred to a 96-well plate, which was then read at 
550 nm using the Synergy HT plate reader.  
Results 
Physicochemical properties and secondary 
structures of MP-C and its analogues 
Both MP-C and cMP-C possessed the same net 
positive charge of +4, which increased to +12 in the 
case of tMP-C (Table 1). Similarly, MP-C and cMP-C 
had a similar degree of hydrophobicity, which was 
dramatically reduced in tMP-C. All three peptides 
adopted α-helical conformations in membrane-mimic 
solution, presenting obviously negative peaks at 222 
nm and 208 nm, with cMP-C presenting the largest 
proportion of an α-helical domain (76% of its 
secondary structure). Despite being designed to be a 
cyclic peptide, 28% of the secondary structure of 
cMP-C unexpectedly retained an α-helical domain in 
an aqueous environment, whereas MP-C and tMP-C 
mainly adopted a random coil structure (Figure 1).  
 
Table 1. Physicochemical properties of MP-C and its two 
analogues. 
Peptide Residues Hydrophobicity Net 
charge 
% α-helix 
10 mM NH4AC 50% TFE (v/v) 
MP-C 14 0.634 +4 7 33 
cMP-C 16 0.748 +4 28 76 
tMP-C 23 0.027 +12 9 28 
 
 
Figure 1. CD spectra for MP-C (dotted line), cMP-C (solid line) and tMP-C 
(dashed line) in 100 µM concentrations in (A) 10mM NH4AC buffer and (B) 50% 
TFE/10mM NH4AC solution at 20 ºC. 
 
Serum stability of peptides 
Peptide degradation analyses showed that MP-C 
began to degrade at a more-or-less linear rate (3.54 % 
h-1) upon being mixed with serum, but that cMP-C 
was not degraded significantly within the first 8 h. 
Thereafter, however, cMP-C also began to degrade at 
about the similar linear rate (4.23 % h-1) such that both 
peptides were degraded significantly (to less than 
40% remaining) after 24 h (Figure 2). On the other 





hand, tMP-C demonstrated poor serum stability, 
which possibly co-precipitated with serum protein by 
intense electrostatic adsorption. 
 
 
Figure 2. The stability of MP-C (red), cMP-C (blue) and tMP-C (green) in 10% 
FBS in RMPI-1640 culture medium at 37 ºC. Data points represent the average 
of three independent experiments with error bars presenting the s.d. 
 
Antimicrobial activity  
Both parent peptide and its analogues displayed 
at least moderate bioactivity again all the 
microorganisms that we examined (Table 2). This was 
especially the case for both MP-C and tMP-C, where 
MIC and MBC values were at most 16 µM and often 
much lower. By contrast, the comparative activity of 
cMP-C was at least 4× lower. Importantly, MP-C and 
tMP-C maintained similar levels of potency against 
the three antibiotic resistant microorganisms, whereas 
the MICs of cMP-C were 4× higher in two of the three 
cases compared to the standard test organisms.  
 
Table 2. Antimicrobial activity of the parent mastoparan peptide 
and its two analogues against various microorganisms. 
Microorganisms MIC/MBC (µM) 
MP-C cMP-C tMP-C 
S. aureus 2/2 32/64 4/4 
E. coli 4/8 32/128 2/2 
C. albicans 4/4 32/128 2/2 
MRSA 4/4 128/128 4/8 
P. aeruginosa 8/16 32/>512 4/4 
E. faecalis 8/8 128/128 8/16 
 
Anti-biofilm activity  
Similarly, both MP-C and tMP-C were able to 
broadly suppress biofilm formation by S. aureus and 
P. aeruginosa (maximum MBIC of 32 µM), but were 
noticeably less effective at eliminating an already 
existing biofilm (Table 3). Again, cMP-C showed less 
potency than the other two peptides and was only 
able to inhibit the formation of biofilm by S. aureus at 
the concentrations that we examined.  
Membrane permeabilisation of S. aureus 
Two distinct behaviours were observed among 
the peptides, with cMP-C again differentiating itself 
from the parent peptide and tMP-C (Figure 3). cMP-C 
caused almost immediate and severe membrane 
permeabilisation, even at the lowest concentration of 
it that we tested (1-fold of its MIC versus S. aureus). 
Significant permeabilisation also occurred at higher 
concentrations of cMP-C, albeit noticeably reduced in 
comparison the base concentration. Analogously, 
relative florescent intensity, which was maximal after 
only a few minutes, also decreased slightly over time 
in the case of cMP-C (Figure 3B) (** P<0.01, compa-
rison between the maximum point in fluorescence 
intensity at the 19th min and end point at the 40th min). 
 
Table 3. Anti-biofilm activity of three peptides against the biofilm 
of S. aureus and P. aeruginosa. 
Microorganisms MBIC/MBEC (µM) 
MP-C cMP-C tMP-C 
S. aureus  4/64 32/>512 32/256 
P. aeruginosa  32/128 >512/>512 8/128 
 
 
Figure 3. Membrane permeabilisation of the Gram-positive bacteria as 
indicated by an increase in the fluorescence of SYTOX Green. (A) 
Permeabilisation after 2 h of incubation with MP-C (solid), cMP-C (hatched) and 
tMP-C (shaded) at 1-, 2- and 4-fold concentrations of their MICs against S. 
aureus. The statistical significance shows in Table S1. (B) Relative fluorescent 
intensity over time of 4-fold MIC of MP-C (red), cMP-C (blue) and tMP-C 
(green) at 4-fold concentrations of the MICs against S. aureus.  
 
By contrast, membrane permeabilisation was 
negligible for both MP-C and tMP-C at the basal 
concentration but increased greatly at concentrations 





of 2- and especially 4-fold their MICs against S. aureus, 
with the increase being larger for MP-C. The 
time-series analysis for these two peptides were also 
similar, with the degree of permeabilisation initially 
increasingly slowly over time such that full 
permeabilisation occurred only after 20 minutes. 
Anti-tumor and haemolytic activity  
MP-C and analogues showed broad-spectrum 
anticancer activities as evidenced by their ability to 
inhibit the proliferation of five diverse human cancer 
cell lines (Figure 4). IC50s for MP-C ranged from 6.26 
to 36.65 µM and were even lower for the two 
analogues (Table 4), 2x in the case of cMP-C (with the 
exception of PC-3) and from 5-11x for tMP-C. For ther 
latter peptide, all IC50s for the cancer cell lines were 
less than 4 µM. 
 
Table 4. Induced cytotoxicity of MP-C and analogues on a panel 
of human cancer cells and normal cells (human HMEC-1 and horse 
erythrocytes). IC50 and HC50 were calculated from the normalized 
curves in Figures 4 and 5 using GraphPad Prism 6 (GraphPad 
Software, USA). 
Cell lines IC50 (μM) 
MP-C cMP-C tMP-C 
H157 13.57 7.02 2.79 
MBD-MB-435S 27.70 13.87 3.86 
PC-3 6.29 13.87 3.86 
U251-MG 36.65 8.56 3.36 
MCF-7 25.27 13.66 3.70 
HMEC-1  57.15 39.53 9.18 
Haemolysis (HC50) of horse erythrocytes 40.11 9.19 77.94 
 
All three peptides showed relatively weaker 
activity against the normal cell line HMEC-1, 
although tMP-C still displayed significant cytotoxicity 
with an IC50 < 10 µM and a 60% inhibitory effect at a 
concentration of 10 µM. By contrast, MP-C and tMP-C 
exhibited moderate hemolytic effects on horse 
erythrocytes, with the potency of tMP-C being greatly 
reduced compared to that against the cancer cells lines 
(Figure 5; Table 4). cMP-C showed high activity 
against the red blood cells at low concentrations (IC50 
< 10 µM) and concentrations that were often lower 
than those for the cancer cell lines. 
Discussion 
Clearly, the venom produced by venomous 
creatures including snakes, jellyfish, cone snails, 
spiders, scorpions as well as some insects like wasps 
have evolved because of their direct benefits to these 
organisms in terms of self-defence and/or prey 
acquisition. However, because the bioactive 
substances from the venom often also possess strong 
antimicrobial and anti-cancer properties (e.g., 
cupiennin 1a from spider 35), they also serve as 
promising drug candidates, justifying their 
identification, isolation, and testing in this context. 
Indeed, some bioactive peptides have even reached 
the clinical trial stage, such as MVIIA (commercial 
name ziconotide 36) and magainin (commercial name 
Pexiganan 37) for the treatment of intractable pain and 
diabetic foot ulcers, respectively. The bioactive 
peptides from wasp venom, like mastoparan, should 
represent a promising source for new drug leads 
discovery and development, having been shown to be 
potent substances with obvious antimicrobial and 
anti-cancer properties 19, 20, 38. Yet, mastoporan have 
not been researched to the same degree in this context 
as have other bioactive peptides derived from other 
insects, and the bee-venom protein mellitin in 
particular, possibly because of potential haemolytic 
activity and other toxic effects 39. 
Indeed, exactly this scenario was mirrored in our 
results, which showed that the natural, parent 
peptide, MP-C, shows strong antimicrobial and 
anticancer properties, with effective concentrations in 
the low micromolar range. MP-C as a typical cationic 
antimicrobial venom Importantly, it displayed about 
the same level of efficacy against both stock and 
resistant bacteria as well as only a slightly reduced 
efficacy against biofilms. However, effective concent-
rations against both the normal human cell line 
HMEC-1 and horse erythrocytes were generally also 
in the low micromolar range, which is problematic for 
the use of MP-C a clinical context. Similar results were 
obtained by Yoon et al. (antimicrobial activity against 
E.coli ATCC 11775 (MIC>1000 µM), S.aureus ATCC 
12600 (MIC=500 µM), C.albicans ATCC 10231 
(MIC=100 µM) and causing no hemolysis to human 
erythrocytes within 200 µM 25), although effective 
concentrations were up to two orders of magnitude 
higher than what we observed. We have no ready 
explanation for this latter discrepancy. 
To potentially ameliorate this situation, we 
turned to two targeted modifications of MP-C in an 
attempt to increase their potency or, more likely given 
its already strong bioacitivties, to reduce its toxicity to 
the host organism. In this regard, targeted 
modification represents an important extension of 
natural drug discovery given that medical 
bioactivities are often useful side-effects of many 
natural compounds that could be improved further. 
However, because the exact mechanism of action of 
most bioactive peptides remains unknown, our 
modifications are often restricted to following general 
guidelines (e.g., beneficial properties that include an 
increased amphipathic nature or cationic charge), 
which was also the case here insofar as our 
modifications were made to either increase the 
stability of the peptide in serum solution (cMP-C) or 
to increase its intracellular delivery (tMP-C). 






Figure 4. The effect on cell proliferation of MP-C (red), cMP-C (blue) and tMP-C (green) on the cancer cell lines (A) H157, (B) MDA-MB-435S, melanocyte, (C) PC-3, 
(D) U251MG, and (E) MCF-7 as well as (F) the normal human microvessel endothelial cell HMEC-1. Data points represent the average of three independent 




Figure 5. Hemolytic activity of MP-C (red), cMP-C (blue) and tMP-C (green) 
against horse red blood cells. Data points represent the average of three 
independent experiments and error bars represent the s.d. The statistical 
significance shows in Table S3. 
 
The results of our modifications were mixed. 
Previous work has indicated that a cysteine knot 
resulting from paired two cysteine amino acids in N- 
and C- termini in a peptide can play an important role 
in maintaining or inducing the bioactive structure of 
the peptide 40, largely by preventing its degradation 
by diverse proteases 41, 42. However, our modification 
of the parent peptide to contain such a head-to-tail 
cyclized structure (as cMP-C) reduced its 
antimicrobial activity notably, despite the latter 
always displaying the greatest α-helical nature of the 
three peptides (even in an aqueous environment), a 
conformation that is supposed to facilitate interaction 
with the cell membrane 43. After confirmation of the 
formation of disulphide bridge in cMP-C by 
MALDI-TOF, we assume that the disulphide bridge 
might be remarkable for stabilising the helical 
structure of cMP-C instead of turning the backbone 
for a β-sheet conformation. Similarly, non-helical coil 
wasp venom peptides, examples like OdVP4, EpVP3, 
EpVP3S, EpVP4a or b, and EpVP5, have neither 
antimicrobial and hemolytic, nor cell lytic activities, 
suggesting helical conformation is crucial property for 
membrane interaction 44, 45. The latter, however, 
probably did occur with non-bacterial (i.e., 
mammalian) cells, where cMP-C showed higher 
(toxic) activity than did the parent peptide as well as 
much higher membrane permeabilisation capabilities. 
(The decreasing ability of cMP-C to permeabilise cell 
membranes at increasingly higher concentrations 
might derive from fluorescence quenching arising 
from the increasing formation of peptide-DNA 
aggregates given that long regions of an α-helical 
conformation could bind to DNA stably 46.) By 
contrast, we hypothesize in the case of bacterial cells 
that the cyclical nature of cMP-C causes it to become 
trapped in the bacterial cell wall or biofilm (unlike the 
linear MP-C and MP-C) following its aggregation on 
the cell surface via electrostatic interaction, requiring 
higher concentrations to reach the cell membrane. 





Further experiments with other (labelled) bioactive 
peptides are needed to determine if this is indeed the 
problem with a cyclical structure and if this problem 
occurs frequently enough such that the increased 
stability offered by the cyclical structure is not 
justified in the face of reduced antimicrobial activities. 
Further investigation, including enzymatic treatments 
or incubation with mimicking-membrane 47, 48, is also 
needed to determine whether cMP-C does indeed 
exhibit increased stability and longevity in vivo. 
Our addition of the TAT peptide to the 
N-terminal of the parent MP-C resulted in little 
change, on average, to the already good antimicrobial 
activities of MP-C, but dramatically improved its 
anticancer properties by a factor of at least five-fold. It 
has previously been reported that the anticancer 
activity of mastoporan occurs generally via lysis of the 
outer cell membrane 49. Instead, our results showed a 
large relative decrease in membrane permeabilisation 
by tMP-C despite the fact that the increased 
cationicity of its N-terminus should enhance its 
electrostatic attraction to the cell membrane, thereby 
reinforcing its cytolytic effects 50. Balancing this, 
however, is that most antimicrobial peptides contain a 
relative hydrophobic segment in their N-terminus, 
presumably to interact with the cell membrane 51, 52. 
Thus, given that the TAT is known to be a short 
cell-penetrating peptide, we suspect an additional, 
intracellular mechanism to explain the increased 
anticancer properties of tMP-C. This in line with 
reports that mastoparan can interact with the 
phospholipid phase of the mitochondrial membrane, 
which has been implicated as the leading cause for 
inducing apoptosis in B16F10-Nex2 melanoma cells 38, 
53, and can selectively activate phospholipase or 
inhibit ATPase activity to cause failure in cell 
proliferation and metabolism 54, 55. The addition of the 
TAT peptide to MP-C would presumably increase 
access to such intracellular targets to induce apoptotic 
cell death 56, 57 while leaving the outer cell membrane 
more intact in comparison to the native peptide. 
However, the poor stability in blood serum and the 
sometimes severe cytolytic effects of tMP-C (e.g., 
versus the normal human cell line HMEC-1) speak 
against its clinical application without further 
modification.  
In summary, our study has reinforced the 
general utility of mastoporan as an alternative to 
conventional antibiotics given its strong antimicrobial 
action that was also evident against resistant bacterial 
strains and those forming biofilms. A necessary step 
in this process, however, is targeted modifications of 
the native peptide to either minimize its potential 
toxic side effects and/or to improve its potency. In the 
latter instance, our addition of the short, 
cell-penetrating peptide TAT to the N-terminus of the 
native peptide increased its activity against cancer 
cells dramatically without any adverse effect on the 
generally good antimicrobial activity. Unfortunately, 
our modifications could not ameliorate the 
occasionally strong cytolytic effects against either 
normal human cells or hose erythrocytes and more 
work here is obviously needed. Another aspect that 
must be considered in the potential clinical 
application of any mastoporan derivative derive from 
reports that MP-C can release histamine from 
mammalian mast cells 24, possibly leading to an 
immune system response. Nevertheless, it is our view 
that mastoporan remains a viable clinical candidate as 
an alternative to conventional antibiotics as well as 
ideal template for designing therapeutic drugs 
through targeted modification. 
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